These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33128369)

  • 21. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France.
    Woudenberg T; Pelleau S; Anna F; Attia M; Donnadieu F; Gravet A; Lohmann C; Seraphin H; Guiheneuf R; Delamare C; Stefic K; Marlet J; Brochot E; Castelain S; Augereau O; Sibilia J; Dubos F; Meddour D; Guen CG; Coste-Burel M; Imbert-Marcille BM; Chauvire-Drouard A; Schweitzer C; Gatin A; Lomazzi S; Joulié A; Haas H; Cantais A; Bertholon F; Chinazzo-Vigouroux MF; Abdallah MS; Arowas L; Charneau P; Hoen B; Demeret C; Werf SV; Fontanet A; White M
    EBioMedicine; 2021 Aug; 70():103495. PubMed ID: 34304047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systems serology detects functionally distinct coronavirus antibody features in children and elderly.
    Selva KJ; van de Sandt CE; Lemke MM; Lee CY; Shoffner SK; Chua BY; Davis SK; Nguyen THO; Rowntree LC; Hensen L; Koutsakos M; Wong CY; Mordant F; Jackson DC; Flanagan KL; Crowe J; Tosif S; Neeland MR; Sutton P; Licciardi PV; Crawford NW; Cheng AC; Doolan DL; Amanat F; Krammer F; Chappell K; Modhiran N; Watterson D; Young P; Lee WS; Wines BD; Mark Hogarth P; Esterbauer R; Kelly HG; Tan HX; Juno JA; Wheatley AK; Kent SJ; Arnold KB; Kedzierska K; Chung AW
    Nat Commun; 2021 Apr; 12(1):2037. PubMed ID: 33795692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019.
    Noh JY; Kwak JE; Yang JS; Hwang SY; Yoon JG; Seong H; Hyun H; Lim CS; Yoon SY; Ryou J; Lee JY; Kim SS; Park SH; Cheong HJ; Kim WJ; Shin EC; Song JY
    J Infect Dis; 2021 Sep; 224(5):754-763. PubMed ID: 34467985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
    Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
    Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections.
    Rijkers G; Murk JL; Wintermans B; van Looy B; van den Berge M; Veenemans J; Stohr J; Reusken C; van der Pol P; Reimerink J
    J Infect Dis; 2020 Sep; 222(8):1265-1269. PubMed ID: 32726417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
    Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
    PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
    Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
    Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Winckelmann AA; Bollerup S; Mikkelsen LS; Sørensen AL; Feng S; Fahnøe U; Lassauniere R; Fomsgaard A; Ramirez S; Weis N; Bukh J
    EBioMedicine; 2021 Sep; 71():103519. PubMed ID: 34419923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Choe PG; Hong J; Park J; Chang E; Kang CK; Kim NJ; Lee CH; Park WB; Oh MD
    J Infect Dis; 2022 Sep; 226(7):1224-1230. PubMed ID: 35299253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked Increase in Avidity of SARS-CoV-2 Antibodies 7-8 Months After Infection Is Not Diminished in Old Age.
    Pichler D; Baumgartner M; Kimpel J; Rössler A; Riepler L; Bates K; Fleischer V; von Laer D; Borena W; Würzner R
    J Infect Dis; 2021 Sep; 224(5):764-770. PubMed ID: 34086960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
    Wajnberg A; Amanat F; Firpo A; Altman DR; Bailey MJ; Mansour M; McMahon M; Meade P; Mendu DR; Muellers K; Stadlbauer D; Stone K; Strohmeier S; Simon V; Aberg J; Reich DL; Krammer F; Cordon-Cardo C
    Science; 2020 Dec; 370(6521):1227-1230. PubMed ID: 33115920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
    Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
    J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection.
    Choteau M; Scohy A; Messe S; Luyckx M; Dechamps M; Montiel V; Yombi JC; Gruson D; Limaye N; Michiels T; Dumoutier L
    Sci Rep; 2022 Feb; 12(1):2077. PubMed ID: 35136139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.
    Cagigi A; Yu M; Österberg B; Svensson J; Falck-Jones S; Vangeti S; Åhlberg E; Azizmohammadi L; Warnqvist A; Falck-Jones R; Gubisch PC; Ödemis M; Ghafoor F; Eisele M; Lenart K; Bell M; Johansson N; Albert J; Sälde J; Pettie DD; Murphy MP; Carter L; King NP; Ols S; Normark J; Ahlm C; Forsell MN; Färnert A; Loré K; Smed-Sörensen A
    JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34665783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
    Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X
    Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
    Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G
    Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.